EDITORIAL
activity status, defined by the absence of relapses and disability progression paralleled by the stable lesion burden, might be predicted in the future.
The increasing number of approved therapies, with distinct mechanisms of actions, indications, efficacy and safety profiles, lead the scientific community to establish therapeutic guidelines. It was recognized that DMD are not the same for all MS patients, neither in all stages, thus, similarly to other autoimmune diseases, such as rheumatoid arthritis, there is usually the need to escalate therapy. There are several clinical treatment guidelines for MS produced by consensus of expert groups in the USA (2002 4 and Spain (2010) 5 . However, as elsewhere stated 6 , there is wide variation in the topics discussed and in the use of pharmacological agents; besides, therapeutic guidelines become quickly outdated in face of new drugs. For instance, fingolimod was considered only in recent consensus 6, 7 . In this line, the article of Finkelsztejn et al., published in this issue, presents the updated version of the 2010 Latin American 8 therapeutic algorithm for relapsing-remitting MS and for clinically isolated syndrome, and it adds very important information. Produced by the Latin American Multiple Sclerosis Forum, which includes experts from eight countries, the algorithm proposes four levels of therapy: first-line and second-line DMD, similar to others, third-line with alemtuzumab or rituximab for aggressive cases and failure of previous drugs, and fourth-line (autologous blood marrow transplant, cyclophosphamide) for especially severe situations; the role of mitoxantrone, other imunossupressants used off-label in MS and generic formulations is also debated; the features of each drug are presented in a practical way, highlighting indications, tolerability, side effects and safety aspects. The authors emphasize that the treatment for MS is a dynamic process due to the approval of new drugs, and their concepts regarding the place of different DMD, therapeutic switch and escalation generally meet the guidelines designed by NorthAmerican and European experts. Yet, the Latin American Multiple Sclerosis Forum questions the direct applicability of those guidelines to Latin American countries, considering that the population of these countries have specific epidemiological, economic and sanitary characteristics. The article also addresses some important topics: pharmacovigilance systems and expenditure coverage; interest of supranational vigilance database for long-term appraisal; access of MS patients to DMD; pediatric MS; disease-free activity as a new therapeutic outcome; importance of cognitive and quality of life assessment with reliable scales.
